New "Skinhibitions(TM)" consumer marketing campaign to increase awareness about its proprietary Sublative(TM) technology offered in the eMatrix, eTwo and elos Plus Systems for both skin rejuvenation ...

LONDON, April 3, 2014 /CNW/ - Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today that its proprietary Sublative™ technology has received CE Mark indication ...

Good day ladies and gentlemen and welcome to the Syneron Third Quarter 2010 Results conference call. At this time all participants are in a listen-only mode. Later we will conduct a question and ...

Syneron Medical Ltd. (NASDAQ: ELOS) held a media panel on the specific challenges of Asian skin and ways to successfully satisfy the increasing demands of Asian consumers regarding skin tone and ...